logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Sitagliptin/pioglitazone for type 2 diabetes mellitus – monotherapy or add-on therapy

< Back

Sitagliptin/pioglitazone for type 2 diabetes mellitus – monotherapy or add-on therapy

Drugs

Endocrine, Nutritional and Metabolic

December 2010


Sitagliptin/pioglitazone (MK-0431C; MK-431C) is a fixed dose combination of sitagliptin, DPP-4 inhibitor, and pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR) agonist. It is intended to substitute sitagliptin or pioglitazone, or to be used as an add-on to metformin, for the treatment of patients with type 2 diabetes who are uncontrolled on metformin in combination with pioglitazone or sitagliptin. In phase III clinical trials, sitagliptin was administered orally at 100mg once daily and pioglitazone was administered orally at 15mg to 45mg once daily.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts